{"#title":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing","#attached":{"library":["mqis\/reports"],"drupalSettings":{"mqis":{"measures":{"110980":{"xcomps":{"2023":"2023"},"ycomps":{"2023":{"0":"40.0","4":"45.1","8":"37.0"}},"complegend":{"0":"New England Medicaid Managed Care CY 2023","4":"National Medicaid Managed Care 75th Percentile CY 2023","8":"NH Commercial CY 2023"},"compdata":{"Comparison Rate":[{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2023","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2022","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2021","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"New England Medicaid Managed Care","data_source":"New England Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"2","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2023","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2022","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2021","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"National Medicaid Managed Care 75th Percentile","data_source":"National Medicaid Managed Care, Quality Compass, NCQA","data_source_order":"3","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2023","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2022","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2021","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"},{"name":"NH Commercial","data_source":"NH Commercial","data_source_order":"14","notes":"","year":"2020","year_type":"CY","measure_name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing"}]},"ymax":115,"comp_table":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing - Comparators (Export<\/a>)<\/span><\/caption>\n \n \n
Original Order\n \n Sort descending\n <\/span>\n<\/span>\n<\/a><\/th>\n Measure ID<\/a><\/th>\n Measure Name<\/a><\/th>\n Comparator Name<\/a><\/th>\n Comparator Type<\/a><\/th>\n Year<\/a><\/th>\n Value<\/a><\/th>\n <\/tr>\n <\/thead>\n \n
0<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n New England Medicaid Managed Care CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
1<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n New England Medicaid Managed Care CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
2<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n New England Medicaid Managed Care CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
3<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n New England Medicaid Managed Care CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
4<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n National Medicaid Managed Care 75th Percentile CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n \u2021<\/td>\n <\/tr>\n
5<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n National Medicaid Managed Care 75th Percentile CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n \u2021<\/td>\n <\/tr>\n
6<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n National Medicaid Managed Care 75th Percentile CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n \u2021<\/td>\n <\/tr>\n
7<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n National Medicaid Managed Care 75th Percentile CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n \u2021<\/td>\n <\/tr>\n
8<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n NH Commercial CY 2023<\/td>\n Comparison Rate<\/td>\n 2023<\/td>\n 37.0<\/td>\n <\/tr>\n
9<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n NH Commercial CY 2022<\/td>\n Comparison Rate<\/td>\n 2022<\/td>\n 36.3<\/td>\n <\/tr>\n
10<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n NH Commercial CY 2021<\/td>\n Comparison Rate<\/td>\n 2021<\/td>\n 32.0<\/td>\n <\/tr>\n
11<\/td>\n HEDIS_APM.02.A<\/td>\n Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing<\/td>\n NH Commercial CY 2020<\/td>\n Comparison Rate<\/td>\n 2020<\/td>\n 27.0<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","xseries":{"2019":"2019","2020":"2020","2021":"2021","2022":"2022","2023":"2023"},"yseries":{"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing":{"2019":"36.1","2020":"31.3","2021":"36.1","2022":"33.1","2023":"37.0"}},"trendlegend":{"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing":"Total (All Subgroups)"},"numerators":{"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing":[367,352,434,385,383]},"denominators":{"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing":[1018,1123,1203,1163,1035]},"timeperiods":{"t_2019-01-01_2019-12-31":{"start":"1546318800","end":"1577768400"},"t_2020-01-01_2020-12-31":{"start":"1577854800","end":"1609390800"},"t_2021-01-01_2021-12-31":{"start":"1609477200","end":"1640926800"},"t_2022-01-01_2022-12-31":{"start":"1641013200","end":"1672462800"},"t_2023-01-01_2023-12-31":{"start":"1672549200","end":"1703998800"}},"data_elements":[{"data_element_id":"253364","identifier":"HEDIS_APM.02.A.C111_NUM","measure_id":"117454","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"1","uploader_user_id":"51","last_modified":"1705429597","spec_id":"761","data_element_class_name":"Numerator"},{"data_element_id":"253365","identifier":"HEDIS_APM.02.A.C111_DEN","measure_id":"117454","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"2","uploader_user_id":"51","last_modified":"1705429609","spec_id":"761","data_element_class_name":"Denominator"},{"data_element_id":"253363","identifier":"HEDIS_APM.02.A.C111_RATE","measure_id":"117454","type":"1","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year.<\/p>","class":"3","uploader_user_id":"51","last_modified":"1705429624","spec_id":"761","data_element_class_name":"Rate"},{"data_element_id":"253362","identifier":"HEDIS_APM.02.A.C111_LCI","measure_id":"117454","type":"1","tech_definition":"

The State of NH DHHS calculates this value based on values submitted in the data-filled workbook utilizing the following formula:<\/p>\r\n\r\n

=(Reported Rate -(1.96*(SQRT((Reported Rate*(1-Reported Rate)\/Eligible Population))))-(1\/(2* Eligible Population)))<\/p>","class":"4","uploader_user_id":"51","last_modified":"1596569513","spec_id":"761","data_element_class_name":"Lower Confidence Interval"},{"data_element_id":"253361","identifier":"HEDIS_APM.02.A.C111_UCI","measure_id":"117454","type":"1","tech_definition":"

The State of NH DHHS calculates this value based on values submitted in the data-filled workbook utilizing the following formula:<\/p>\r\n\r\n

=(Reported Rate +(1.96*(SQRT((Reported Rate*(1-Reported Rate)\/Eligible Population))))+(1\/(2* Eligible Population)))<\/p>","class":"5","uploader_user_id":"51","last_modified":"1596569534","spec_id":"761","data_element_class_name":"Upper Confidence Interval"}],"data_table":"\n \n \n \n \n \n \n \n \n
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing (Export<\/a>)<\/span><\/caption>\n \n \n
Time Period<\/th>\n Measure Name<\/th>\n Measure Numerator<\/th>\n Measure Denominator<\/th>\n Measure Rate<\/th>\n Confidence Interval<\/th>\n <\/tr>\n <\/thead>\n \n
2019-01-01 - 2019-12-31<\/td>\n Total (All Subgroups)<\/td>\n 367<\/td>\n 1,018<\/td>\n 36.1%<\/td>\n 33.1 - 39.1<\/td>\n <\/tr>\n
2020-01-01 - 2020-12-31<\/td>\n Total (All Subgroups)<\/td>\n 352<\/td>\n 1,123<\/td>\n 31.3%<\/td>\n 28.6 - 34.0<\/td>\n <\/tr>\n
2021-01-01 - 2021-12-31<\/td>\n Total (All Subgroups)<\/td>\n 434<\/td>\n 1,203<\/td>\n 36.1%<\/td>\n 33.4 - 38.8<\/td>\n <\/tr>\n
2022-01-01 - 2022-12-31<\/td>\n Total (All Subgroups)<\/td>\n 385<\/td>\n 1,163<\/td>\n 33.1%<\/td>\n 30.4 - 35.8<\/td>\n <\/tr>\n
2023-01-01 - 2023-12-31<\/td>\n Total (All Subgroups)<\/td>\n 383<\/td>\n 1,035<\/td>\n 37.0%<\/td>\n 34.1 - 39.9<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n","suppressed":false,"orgs":{"MCM: AmeriHealth Caritas NH":12,"MCM: NH Healthy Families":1,"MCM: Well Sense":3,"MCM: Meridian":2},"qualifiers":{"2019":[],"2020":[],"2021":[],"2022":[],"2023":[],"":["The aggregated values do not include data for all organizations. Customize this report by organization for details."]},"verifieds":{"2019":{"3":false,"1":false},"2020":{"12":false,"1":false,"3":false},"2021":{"3":false,"1":false,"12":false},"2022":{"3":false,"1":false,"12":false},"2023":{"1":false,"12":false,"3":false}},"measure":{"measure_id":"117453","identifier":"HEDIS_APM.02.A","name":"Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) - Cholesterol Testing","description":"

HEDIS\u00ae Measurement Definition:<\/p>\r\n\r\n

The percentage of children and adolescents 1\u201317 years of age who had two or more antipsychotic prescriptions and had metabolic testing: Cholesterol testing.<\/p>","tech_definition":"

See HEDIS\u00ae Technical Specifications for Health Plans Volume 2 for the relevant measurement year..<\/p>","relevance":"

This measure captures the percent of children 1-17 years of age who are taking two or more antipsychotic medications and had cholesterol testing.  Some people who take antipsychotic medication gain weight and being overweight places them at a higher risk for developing diabetes over time.  A low or falling rate may indicate that children taking antipsychotic medications are not being routinely screened for diabetes and this may lead to an increase in undiagnosed diabetes.  This measure captures the number of children 1-17 years of age who taking two or more antipsychotic medications and had cholesterol testing, divided by the total eligible population, as a percentage.<\/p>","tech_definition_owner_id":"0","steward_id":"3","data_source":"6","rate_source":"1","rate_formula":"c:1|\/|c:2|*|100","parent_measure_id":"0","uploader_user_id":"47","submission_frequency":"4","reporting_period_min":"1546318800","reporting_period_max":"4102376400","last_modified":"1730216566","spec_id":"761","rate_precision":"1","rate_type":"1","steward_measure_id":"APM","requirement_source":"Exhibit O","optional_exclusions":"","comments":"","subpopulation":"0","summary_of_changes":"